Published: 2022-02-23

Topical therapy of various dermatoses with ImpoyzTM (clobetasol propionate) cream 0.025%

Mahendra Haribhai Vaghasiya, Sanjay Kumar Dayani, Ravi Munasing Rathod, Arun Kumar Chatterjee, Balachandra S. Ankad, Saleem Abdulhasanbeg Jamadar, Umesh Omkarlal Agrawal, Jayesh Sanaryia Amrutlal, Mahendra Kumar Singhi, Mashkoor Ahmed Wani


The most widely prescribed drugs for the treatment of a variety of dermatoses are Topical corticosteroids (TC). These medications are approved for the treatment of inflammatory and pruritic manifestations of dermatologic disorders due to their powerful symptom-relieving impact. Clobetasol propionate (CP) is the most popular (TC) used to relieve itching, redness, and oedema caused by a variety of skin disorders. Anti-inflammatory, anti-pruritic, and vasoconstrictive characteristics are all present in it. CP works by binding to cytoplasmic glucocorticoid receptors and activating glucocorticoid receptor-mediated gene expression, resulting in the production of anti-inflammatory proteins while suppressing the production of inflammatory mediators. The formulation is free from known contact allergens, such as propylene glycol, short-chain alcohols, and sorbitol-based emulsifiers, and has demonstrated hypoallergenic effects. The efficacy, safety, and clinical experience of utilizing CP 0.025% cream for the treatment of various dermatologic disorders are discussed in this case series.



Clobetasol propionate 0.025%, Plaque psoriasis, Psoriasis, Topical corticosteroids

Full Text:



Das A, Panda S. Use of Topical Corticosteroids in Dermatology: An Evidence-based Approach. Indian J Dermatol. 2017;62(3):237-50.

Castela E, Archier E, Devaux S, Gallini A, Aractingi S, Cribier B, et al. Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities. J Eur Acad Dermatol Venereol. 2012;26(3):36-46.

Gabros S, Nessel TA, Zito PM. Topical Corticosteroids. Treasure Island, FL: StatPearls Publishing; 2022.

Rosso JQ. Topical Corticosteroid Therapy for Psoriasis-A Review of Clobetasol Propionate 0.025% Cream and the Clinical Relevance of Penetration Modification. J Clin Aesthet Dermatol. 2020;13(2):22-9.

Sidgiddi S, Naqvi SMH, Shenoy M, Balraj DN, Kothari J, Gupta S, et al. Efficacy and Safety of Novel Formulation of Clobetasol Propionate 0.025% Cream in Indian Moderate-to-Severe Psoriasis Patients: Phase-2a, Randomized 3-Arm Study. Dermatol Ther (Heidelb). 2021;11(5):1717-32.

Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):15354.